GSK3B and Alzheimer disease: In the Wnt/GSK-3β hypothesis of AD [43, 44], Aβ has been suggested to inhibit Wnt signaling and induce the activation of GSK-3β, known as Tau kinase I. The activation of GSK-3β induces an increase in the tau pathology associated with decreases and deficits in neurons [45].